Evidence for low risk of Clostridium difficile infection associated with tigecycline.
Broad-spectrum antibiotics are often associated with a relatively high risk of Clostridium difficile infection (CDI). However, exceptions to this rule, e.g., piperacillin-tazobactam, show that marked inhibition of gut flora is not synonymous with CDI risk. Tigecycline has marked broad-spectrum activity that includes Gram-positive and Gram-negative facultative and obligate anaerobes. Antibiotic susceptibility, gut model and clinical trial data suggest that tigecycline is associated with a relatively low risk of CDI. Further clinical data should be obtained to confirm the results of these initial studies.
Wilcox
M H
MH
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000494:pharmacology; D016360:Clostridioides difficile / Q000187:drug effects* / Q000472:pathogenicity*; D004761:Enterocolitis, Pseudomembranous / Q000382:microbiology*; D005260:Female; D006801:Humans; D007422:Intestines / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D012307:Risk Factors; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline